Cellectis (CLLS) Stock Price, Quote, News & History

Cellectis SA (CLLS) Stock Price, Quote, News & History

CLLSNASDAQ

Trade with Public

$4.28

0.6919.22%

At close: Apr 13, 5:00 PM EST

$4.36

0.081.87%

After Hours: 6:01 PM EST

Key Statistics

Open

$4.32

$4.28

Volume / Avg.

320.69K / 41.51K

Day Range

$4.03 - $4.55

52 Wk Range

1.20 - 5.48

Market Cap

$438.58M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

9.4

Recent Cellectis SA News

Allogene Therapeutics Stock Hits 52-Week High - Here's Why

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.

Vandana Singh

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.

Vandana Singh

Why Cellectis Stock Is Trading Higher Today

Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion efficiency and supports long-term therapeutic potential.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-39.40M

Investing Cash Flow (TTM)

-29.48M

Financing Cash Flow (TTM)

-16.76M

Free Cash Flow (TTM)

-42.93M

Capital Expenditure (TTM)

-3.53M

Net Change in Cash (TTM)

-85.65M

Valuation Metrics

Enterprise Value

$256.96M

PE Ratio (TTM)

PE Ratio (FWD)

PEG Ratio (TTM)

PS Ratio (TTM)

4.93

PB Ratio (TTM)

4.76

Earnings Yield % (TTM)

-18.78%

Earnings Yield % (FWD)

EV / EBITDA (TTM)

Price / EBITDA (TTM)

Price / Free Cash Flow (TTM)

Book Value / Share

$0.75

Company Debt

Total Debt

$55.31M

LT Debt

$51.22M

LT Debt Issuance (TTM)

LT Debt Repayment (TTM)

-$16.19M

Total Cash

$61.53M

Debt to Equity

1.20

Issuance of Debt (TTM)

-$16.19M

Repayment of Debt (TTM)

-$16.19M

Key Statistics

Open

$4.32

$4.28

Volume / Avg.

320.69K / 41.51K

Day Range

$4.03 - $4.55

52 Wk Range

1.20 - 5.48

Market Cap

$438.58M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

9.4

About

Sector

Health Care

Industry

Biotechnology

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cellectis (CLLS) stock?

You can purchase shares of Cellectis (NASDAQ:CLLS) through any online brokerage.

View our list of the best stock brokerages

Who are Cellectis (CLLS) competitors?

There are no as such competitors for Cellectis.

What is the forecast, or price target, for Cellectis (CLLS) stock?

There is no analysis for Cellectis to provide a consensus price target.

What is the current price for Cellectis (CLLS)?

The stock price for Cellectis (NASDAQ: CLLS) is $4.36 last updated April 13, 2026 at 6:01 PM EDT.

Does Cellectis (CLLS) pay a dividend?

There are no upcoming dividends for Cellectis.

When is Cellectis (NASDAQ:CLLS) reporting earnings?

Cellectis does not have any upcoming earnings scheduled.

Is Cellectis (CLLS) going to split?

There is no upcoming split for Cellectis.

What sector and industry does Cellectis (CLLS) operate in?

Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Key Statistics

Open

$4.32

$4.28

Volume / Avg.

320.69K / 41.51K

Day Range

$4.03 - $4.55

52 Wk Range

1.20 - 5.48

Market Cap

$438.58M

P/E Ratio

Dividend Yield

Exchange

NASDAQ

RSI

Short Interest

Days to Cover

9.4

Recent Cellectis SA News

Allogene Therapeutics Stock Hits 52-Week High - Here's Why

Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.

Vandana Singh

Allogene Arbitration Victory Pressures Cellectis Shares Tuesday

Cellectis shares fell after Allogene cited a favorable arbitration ruling confirming control of cema-cel and outlining key CAR-T milestones.

Vandana Singh

Why Cellectis Stock Is Trading Higher Today

Cellectis reports strong Nature Communications data showing CssDNA boosts non-viral gene insertion efficiency and supports long-term therapeutic potential.

Vandana Singh